Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis [0.03%]
PCSK9抑制剂自我注射后市场报道的用药剂量不全相关的并发症：一项描述性研究和非对比分析
Richard H Woods
Richard H Woods
Background: Evolocumab and alirocumab are self-injected proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors indicated for low-density lipoprotein cholesterol reduction. Complications in the use or functionali...
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly [0.03%]
英夫利昔单抗在波兰专利过期后的市场成本动态：从参考药物竞争到生物类似药垄断
Marcin Stajszczyk,Krzysztof Batko,Zbigniew Michał Żuber et al.
Marcin Stajszczyk et al.
Objectives: To evaluate the pricing of etanercept (ETN) reference and biosimilar drugs in a changing competitive to monopolized market. Methods: ...
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers [0.03%]
抗原依赖的抗体药物偶联物可作为驱动基因改变阳性或阴性的非小细胞肺癌的新型治疗药物
Laura Bender Somme,Christos Chouaid,Fabien Moinard-Butot et al.
Laura Bender Somme et al.
Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung...
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges [0.03%]
癌症免疫治疗中新兴的先天性免疫细胞：机遇与挑战
Jennifer Wu
Jennifer Wu
Immune checkpoint inhibitor (ICI)-based therapy has made an unprecedented impact on survival benefit for a subset of cancer patients; however, only a subset of cancer patients is benefiting from ICI therapy if all cancer types are considere...
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs [0.03%]
法国早期通道改革对肿瘤学创新的影响：批准、患者和成本
Tess Martin,Catherine Rioufol,Bertrand Favier et al.
Tess Martin et al.
Background: An ambitious reform of the early access (EA) process was set up in July 2021 in France, aiming to simplify procedures and accelerate access to innovative drugs. ...
Muhammad Shahzad Rafiq,Muhammad AbuBakar Shabbir,Ahmed Raza et al.
Muhammad Shahzad Rafiq et al.
Antimicrobial resistance (AMR) can potentially harm global public health. Horizontal gene transfer (HGT), which speeds up the emergence of AMR and increases the burden of drug resistance in mobile genetic elements (MGEs), is the primary met...
Kouhei Tsumoto,Tsutomu Takeuchi
Kouhei Tsumoto
Biologic therapy involving anti-tumor necrosis factor-α (anti-TNFα) agents has fundamentally changed the management of patients with immune-mediated inflammatory diseases, including rheumatoid arthritis, thus benefiting many patients. Nev...
Wei Wang,Ying Liu,Zuo-Bin Zhu et al.
Wei Wang et al.
Erectile dysfunction (ED) is a common clinical condition that mainly affects men aged over 40 years. Various causes contribute to the progression of ED, including pelvic nerve injury, diabetes, metabolic syndrome, age, Peyronie's disease, s...
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching [0.03%]
在扩大患者群体和新适应症中获得的额外数据支持生物仿制药互换实践
Hillel P Cohen,Wolfram Bodenmueller
Hillel P Cohen
As of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic. Most studies evaluated infliximab, wh...
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database [0.03%]
严重哮喘生物疗法的安全性：世卫组织药品警戒数据库中报告的疑似不良反应分析
Paola Maria Cutroneo,Elena Arzenton,Fabiana Furci et al.
Paola Maria Cutroneo et al.
Background: The management of uncontrolled severe asthma has greatly improved since the advent of novel biologic therapies. Up to August 2022, five biologics have been approved for the type 2 asthma phenotype: anti-IgE (o...